Autorisation d’accès précoce refusée à la spécialité TEPEZZA (téprotumumab) dans l'indication « traitement des patients adultes atteints d’ophtalmopathie basedowienne modérée à sévère ».
See also
HAS opinions and decisions
26/02/2025
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
gWeW3kDNRmpfwSNR
